Funding news
Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc. Raises $21

Recently funded · $21.0M Series bHospitals and Health CareUSView source

Get the full Aclaris Therapeutics, Inc. company profile

Access contacts, investors, buying signals & more

Open in Dashboard

For patients grappling with immuno-inflammatory diseases and few treatment options, Aclaris Therapeutics, Inc. is working to change the landscape. The clinical-stage biopharmaceutical company has now secured $21.0M in Series b funding to advance its pipeline of novel drug candidates.

Aclaris's multi-stage portfolio is powered by a robust R&D engine, which explores protein kinase regulation to develop new therapies. This capital infusion will support the continued development of these candidates, aiming to address significant unmet medical needs.

Other United States companies recently funded

View all

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#CompanyAmount
1
Shockwave Medical logo

Shockwave Medical

United States

$13.1B
2
NeuroEM Therapeutics logo

NeuroEM Therapeutics

United States

$7.2B
3
Illumina logo

Illumina

United States

$7.1B
4
GRAIL logo

GRAIL

United States

$7.1B
5
RemeGen Biosciences logo

RemeGen Biosciences

United States

$5.6B

Other recent Series b rounds

Companies that recently closed a Series b round.

#CompanyAmount
1
Catch Co. logo

Catch Co.

United States

$38.0M
2
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc.

United States

$60.0M
3
BlackSwan Technologies logo

BlackSwan Technologies

United Kingdom

$79.3M
4
Unity logo

Unity

United States

$12.0M
5
Insolight logo

Insolight

Switzerland

$5.0M